171663-06-2

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 65185-58-2 2-(2-bromophenyl)ethanamine 
• 19472-74-3 2-(2-bromophenyl)acetonitrile 

Downstream Products

• 918958-56-2 {2-[2-(4-hydroxy-but-1-ynyl)-phenyl]-ethyl}-carbamic acid tert-butyl ester 
• 688011-04-3 (2-{2-[3,3-dimethoxy-6-(2-methoxy-ethyl)-4-oxo-cyclohexa-1,5-dienyl]-phenyl}-ethyl)-carbamic acid tert-butyl ester 
• 1059681-96-7 N-(2-(2-bromophenyl)-ethyl)-N-tert-butoxycarbonyl-2-propynylamine 
• 500876-19-7 N-Boc-N-methyl-N-(2-(2-bromophenyl)ethyl)amine 
• 1198271-92-9 (3S)-(E)-N-Boc-N-[2-[2-(3-hydroxy-1-butenyl)phenyl]ethyl]amine 
• 1198272-00-2 (3S)-(E)-N-Boc-N-[2-[2-(3-hydroxy-1-pentenyl)phenyl]ethyl]amine 
• 1273547-13-9 (3S)-(Z)-N-Boc-N-[2-[2-(3-hydroxy-1-butenyl)phenyl]ethyl]amine 
• 1273547-14-0 (3S)-(E)-N-Boc-N-[2-[2-(3-acetoxy-1-butenyl)phenyl]ethyl]amine 
• 1358685-58-1 C₂₂H₂₈N₂O₄S 
• 1358685-65-0 C₂₃H₃₀N₂O₄S 
• 1086601-80-0 [2-(2-{2-[5-fluoro-2-(2-[1,2,3]triazol-1-yl-ethylamino)-pyrimidin-4-yl]-benzo[b]thiophen-7-yl}-phenyl)-ethyl]-carbamic acid tert-butyl ester 
• 1358685-55-8 C₂₃H₃₈N₂O₄S 
• 1358685-52-5 C₁₉H₃₀N₂O₄S 
• 918958-58-4 {2-[2-(3-hydroxy-prop-1-ynyl)-phenyl]-ethyl}-carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

First Contact: 7-Phenyl-2-Aminoquinolines, Potent and Selective Neuronal Nitric Oxide Synthase Inhibitors That Target an Isoform-Specific Aspartate

Inhibition of neuronal nitric oxide synthase (nNOS), an enzyme implicated in neurodegenerative disorders, is an attractive strategy for treating or preventing these diseases. We previously developed several classes of 2-aminoquinoline-based nNOS inhibitor

2-substituted diphenyl sulfide derivative and application thereof

The invention discloses a 2-substituted diphenyl sulfide derivative and application thereof, and a drug composition comprising the compound, which can be used for inhibiting re-uptake of serotonin. The invention further relates to methods of preparing the

Palladium-Catalyzed C(sp2)-H Olefination of Free Primary and Secondary 2-Phenylethylamines: Access to Tetrahydroisoquinolines

A rapid construction of THIQs by a Pd(II)-catalyzed C(sp2)-H olefination of free primary and secondary 2-phenylethylamines with high step- and atom-economy was reported. Notably, no substituent was required at the α-position to the amino group of the 2-phenylethylamines. The substrate scope was broad, and the reaction could also be applied to generate THIQs from the biologically active molecules such as the drug molecule baclofen and phenylalanine ester.

2-METHYL-QUINAZOLINES

The present invention describes 2-methyl-quinazoline compounds of general formula (I), methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions. The 2-methyl substituted quinazoline compounds of general formula(I) effectively and selectively inhibit the Ras-Sos interaction without significantly targeting the EGFR receptor. They are therefore useful for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, such as cancer as a sole agent or in combination with other active ingredients.

Phenethyl nicotinamides, a novel class of NaV1.7 channel blockers: Structure and activity relationship

The NaV1.7 ion channel is an attractive target for development of potential analgesic drugs based on strong genetic links between mutations in the gene coding for the channel protein and inheritable pain conditions. The (S)-N-chroman-3-ylcarboxamide series, exemplified by 1, was used as a starting point for development of new channel blockers, resulting in the phenethyl nicotinamide series. The structure and activity relationship for this series was established and the metabolic issues of early analogues were addressed by appropriate substitutions. Compound 33 displayed acceptable overall in vitro properties and in vivo rat PK profile.

Synthesis of chiral 1-substituted tetrahydroisoquinolines by the intramolecular 1,3-chirality transfer reaction catalyzed by Bi(OTf)3

The intramolecular 1,3-chirality transfer reaction of chiral amino alcohols 1 with 99% ee was developed to construct chiral 1-substituted tetrahydroisoquinoline 2. Bi(OTf)3 (10 mol %)-catalyzed cyclization of 1 (R = H) afforded (S)-1-(E)-propenyl tetrahydroisoquinoline 2 (R = H) in 83% yield with a ratio of 98:2. The stereochemistry at the newly formed chiral center was produced by a syn SN2′-type process. In this reaction, the substituent on the benzene ring of 1 significantly affected the reactivities and selectivities. A plausible reaction mechanism was proposed.

Optimization of the potency and pharmacokinetic properties of a macrocyclic ghrelin receptor agonist (Part I): Development of ulimorelin (TZP-101) from Hit to Clinic

High-throughput screening of Tranzyme Phar-ma's proprietary macrocycle library using the aequorin Ca2+-bioluminescence assay against the human ghrelin receptor (GRLN) led to the discovery of novel agonists against this G-protein coupled receptor. Early hits such as 1 (Ki = 86 nM, EC50 = 134 nM) though potent in vitro displayed poor pharmacokinetic properties that required optimization. While such macrocycles are not fully rule-of-five compliant, principally due to their molecular weight and clogP, optimization of their pharmacokinetic properties proved feasible largely through conformational rigidification. Extensive SAR led to the identification of 2 (Ki = 16 nM, EC50 = 29 nM), also known as ulimorelin or TZP-101, which has progressed to phase III human clinical trials for the treatment of postoperative ileus. X-ray structure and detailed NMR studies indicated a rigid peptidomimetic portion in 2 that is best defined as a nonideal type-I′ β-turn. Compound 2 is 24% orally bioavailable in both rats and monkeys. Despite its potency, in vitro and in gastric emptying studies, 2 did not induce growth hormone (GH) release in rats, thus demarcating the GH versus GI pharmacology of GRLN. (Figure presented)

Lewis acid-catalyzed intramolecular amination via 1,3-chirality transfer

Direct intramolecular amination of the chiral non-racemic allylic alcohol 1 conjugated with a benzene ring afforded the tetrahydroisoquinoline 2 possessing a newly formed alkene in the presence of a catalytic amount of Lewis acid.

The endocyclic restriction test: The geometries of nucleophilic substitutions at sulfur(VI) and sulfur(II)

(Chemical Equation Presented) The trajectories for nucleophilic substitutions at sulfur(VI) and sulfur(II) have been investigated by the endocyclic restriction test. On the basis of double-labeling experiments, the sulfur(VI) transfer in the conversion of 1 to 2 is found to be intramolecular, while the sulfur(VI) transfer in the conversion of 3 to 4 and the sulfur(II) transfer in the conversion of 5 to 6 are found to be intermolecular. These results are taken to be consistent with transition structures for these sulfur transfer reactions which require a large angle between the entering and leaving group, a geometry analogous to apical group positions in trigonal bipyramidal transition states.

A mild inter- and intramolecular amination of aryl halides with a combination of CuI and CsOAc

A unique combination of CuI and CsOAc was found to catalyze aryl amination under mild conditions. The reaction takes place at room temperature or at 90 °C with broad functional group compatibility. The intramolecular reaction was able to form five-, six-, and seven-membered rings with various protecting groups on the nitrogen atom. The scope of the intermolecular amination, as well as its applications to unsymmetrical N,N′-dialkylated phenylenediamines, was investigated.